Log in

Relevant bibliographies by topics / Re-188 / Journal articles

To see the other types of publications on this topic, follow the link: Re-188.

Journal articles on the topic 'Re-188'

Author: Grafiati

Published: 4 June 2021

Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Re-188.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Rhodes, B. A., C. R. Lambert, M. J. Marek, F. F. Knapp, and E. B. Harvey. "Re-188 labelled antibodies." Applied Radiation and Isotopes 47, no. 1 (January 1996): 7–14. http://dx.doi.org/10.1016/0969-8043(95)00262-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Argyrou, Maria, Alexia Valassi, Maria Andreou, and Maria Lyra. "Rhenium-188 Production in Hospitals, by W-188/Re-188 Generator, for Easy Use in Radionuclide Therapy." International Journal of Molecular Imaging 2013 (April 9, 2013): 1–7. http://dx.doi.org/10.1155/2013/290750.

Full text

Abstract:

Rhenium-188 (Re-188) is a high energy -emitting radioisotope obtained from the tungsten-188/rhenium-188 (W-188/Re-188) generator, which has shown utility for a variety of therapeutic applications in nuclear medicine, oncology, and interventional radiology/cardiology. Re-188 decay is accompanied by a 155 keV predominant energy -emission, which could be detected by -cameras, for imaging, biodistribution, or absorbed radiation dose studies. Its attractive physical properties and its potential low cost associated with a long-lived parent make it an interesting option for clinical use. The setup and daily use of W-188/Re-188 generator in hospital nuclear medicine departments are discussed in detail. The clinical efficacy, for several therapeutic applications, of a variety of Re-188-labeled agents is demonstrated. The high energy of the -emission of Re-188 is particularly well suited for effective penetration in solid tumours. Its total radiation dose delivered to tissues is comparable to other radionuclides used in therapy. Furthermore, radiation safety and shielding requirements are an important subject of matter. In the case of bone metastases treatment, therapeutic ratios are presented in order to describe the efficacy of Re-188 usage.

APA, Harvard, Vancouver, ISO, and other styles

3

Tishchenko, V. K., V. M. Petriev, O. P. Vlasova, and E. D. Stepchenkova. "Effect of administration route on the biodistribution of albumin microspheres labelled with Re-188." "Radiation and Risk" Bulletin of the National Radiation and Epidemiological Registry 30, no. 4 (2021): 85–93. http://dx.doi.org/10.21870/0131-3878-2021-30-4-85-93.

Full text

Abstract:

Nowadays the radiolabeled microspheres are established tools for radioembolization of primary and metastatic liver cancer. Human serum albumin microspheres (HSA) are unique carriers for selective and controlled radionuclide delivery to malignant tumors. Rhenium-188 (Re-188), which decays with beta particles (2.12 MeV (71.1%) and 1.965 MeV (25.6%) and gamma emission (155 keV (15.1%)) is one of the most available and promising generator-based radionuclide for cancer therapy. The purpose of this work was to study the biodistribution of microspheres based on hu-man serum albumin labeled with Re-188 (Re-188-HSA) in animals after different routes of admin-istration. The size of more than 95% of microspheres was 10-20 μm. The studies were carried out on outbred white mice and inbred C57BL/6 mice with transplanted Lewis adenocarcinoma after intravenous, intramuscular and intratumoral administration. After intravenous injection the high-est amount of Re-188-HSA in organs and tissues was observed: up to 311.3%/g in lungs, up to 74.30%/g in thyroid gland, up to 12.70%/g in liver, up to 0,81%/g in blood. After the intramuscular injection of 188Re-HSA, the concentration of 188Re-HSA in organs and tissues was significantly lower and did not exceed 1%/g, except for thyroid gland (1,10-17.80%/g). After intratumoral injec-tion the amount of Re-188-HSA in tumor varied from 16.7 to 26.8%/g, that was higher as compared with other organs and tissues. Thus, the routes of Re-188-HSA administration significantly affect its behavior in the body. The obtained results can be used to evaluate the Re-188-HSA potential for radionuclide tumor therapy after intravascular or intratumoral administration.

APA, Harvard, Vancouver, ISO, and other styles

4

Durack, L., J. Eary, J. Vanderheyden, and D. Williams. "GAMMA CAMERA IMAGING OF Re-188 AND Re-186." Clinical Nuclear Medicine 13, Supplement (September 1988): P13. http://dx.doi.org/10.1097/00003072-198809001-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

EARY, J. F., L. DURACK, D. WILLIAMS, and J.-L. VANDERHEYDEN. "Considerations for Imaging Re-188 and Re-186 Isotopes." Clinical Nuclear Medicine 15, no. 12 (December 1990): 911–16. http://dx.doi.org/10.1097/00003072-199012000-00013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Kodina, G. E., A. O. Malysheva, O. Е. Klementyeva, N. A. Taratonenkova, E. A. Lyamtseva, M. V. Zhukova, and A. S. Krasnoperova. "«Synoren, Re-188» – a promising radiopharmaceutical for radiosynovectomy." "Radiation and Risk" Bulletin of the National Radiation and Epidemiological Registry 27, no. 4 (2018): 76–86. http://dx.doi.org/10.21870/0131-3878-2018-27-4-76-86.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Franke, W. G., J. Kropp, R. Koch, R. Runge, R. Hliscs, and K. Liepe. "Comparison of Rhenium-188, Rhenium-186-HEDP and Strontium-89 in palliation of painful bone metastases." Nuklearmedizin 39, no. 06 (2000): 146–51. http://dx.doi.org/10.1055/s-0038-1632262.

Full text

Abstract:

Summary Aim: Several radiopharmaceuticals were compared previously with regard to the efficiency in pain palliation of bone metastases. Furthermore, first results were reported on the suitability for such kind of therapy of the generator produced radionuclide rhenium-188. Method: Influence of Rhenium-188-HEDP (Re-188), Rhenium-186-HEDP (Re-186) and Strontium-89 (Sr-89) on pain symptoms and bone marrow function were obtained in 44 patients (pts). These were 16 pts. with Re-188 (2943 ± 609 MBq), 13 pts. with Re-186 (1341 ± 161 MBq) and 15 pts. with Sr-89 (152 ±18 MBq) (6 woman with breast cancer and 38 mens with prostata cancer). Results: 81 of pts. after Re-188,77% after Re-186 and 80 % after Sr-89 reported relief of pain. The Karnofsky-lndex established by pts. increased from 74 ± 9% to 85 ± 11 % after Re-188, from 70 ± 1 1 % to 76 ± 1 1 % after Re-186 and from 62 ± 10% to 69 ± 10% after Sr-89. However, the difference between the pre- and the post-therapeutic value is only statistically significant in the case of Re-188 therapy (p = 0.001 ). A decrease of platelets of 30 ± 14% after 2.8 ± 0.7 for pts. treated with Re-188, of 39 ± 20% after 3.7 ± 1.0 weeks for pts. treated with Re-186 and of 34 ± 26% after 4.4 ± 1.0 weeks for pts. treated with Sr-89 compared to the value before therapy was observed. The difference was not significant between the 3 groups of pts. (p= 0.125 to 0.862). Conclusion: All tried radiopharmaceuticals were effective in pain palliation. The various radionuclides had no significant difference in the pain relief or the bone marrow impairment. If only the Karnofsky-lndex after Re-188 HEDP seems to be a little more increase.

APA, Harvard, Vancouver, ISO, and other styles

8

Edelman, M. J., G. Clamon, D. Kahn, M. Magram, and B. R. Line. "Targeted radiopharmaceutical therapy for advanced lung cancer: Phase I trial of rhenium Re188 somatostatin analogue P2045." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 7672. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7672.

Full text

Abstract:

7672 Background: Both small cell (SCLC) and non-small cell lung cancer (NSCLC) overexpress somatostatin receptors (SSTR). P2045 peptide is an 11-amino acid somatostatin analogue that binds with high affinity to SSTR. The analogue can be labeled with Tc-99m to gauge receptor prevalence, or with Re-188 for 2.1MeV beta radiotherapy. To evaluate the safety of this approach a phase I dose-escalation study of Re-188 P2045 in SSTR positive lung cancer was performed. Methods: Patients (pts) were required to have progressive advanced lung cancer, PS 0–1, and normal organ function. There were no limitations on the number of prior therapies. Tumor SSTR was detected with Tc-99m P2045. If positive, treatment with escalating doses of Re-188 P2045 was instituted. Three doses were evaluated, 30 mCi/m2, 60 mCi/m2 and 90 mCi/m2. A single dose of Re-188 P2045 was allowed. Dose limiting toxicity was defined as ≥ grade 3 non-hematologic toxicity, grade 4 hematologic toxicity or projected renal radiation dose of >20 Gy. Results: 15 pts entered, 7 M, 8 F, median age 61y, 9-PS0, 6 PS1. 13 NSCLC, 2 SCLC. 14 pts had ≥ 2 prior chemotherapy regimens. 1 pt refused standard therapy. All pts were imaged with Tc-99m P2045, 8 pts received Re-188 P2045. The 7 pts who did not proceed to Re-188 P2045 were due to rapid progression (n=2) non-uptake of Tc 99m P2045 (n=2) or projected renal radiation dose above the 20 Gy limit (n=3). All pts treated with Re-188 P2045 (4 at 30 mCi/m2, 3 at 60 mCi/m2 and 1 at 90 mCi/m2) had NSCLC. The major toxicity was grade 1 or 2 lymphopenia. No dose limiting toxicities were seen. All tumors imaged by Tc-99m had uptake of Re- 188. The trial was halted at the 90 mCi/m2 level when 3 pts had projected renal radiation doses above 20Gy. No responses were seen. 5 of the 8 pts (62.5%, 95% CI: 24%, 91%) had stable disease at 8 weeks, all of whom entered with progressive disease.. Median overall survival was 11.5 mo. Conclusions: 1) Re-188 P2045 was well-tolerated. 2) Tc-99m P2045 imaging allows identification of pts who may benefit from Re-188 P2045. 3) While responses were not seen, survival for these heavily pretreated pts is encouraging. 4) Further exploration of this approach utilizing amino acid infusion to ameliorate potential renal toxicity is warranted. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

9

Häfeli, Urs O., William K. Roberts, Dominik S. Meier, Jay P. Ciezki, Gayle J. Pauer, Eric J. Lee, and Martin S. Weinhous. "Dosimetry of a W-188/Re-188 beta line source for endovascular brachytherapy." Medical Physics 27, no. 4 (April 2000): 668–75. http://dx.doi.org/10.1118/1.598928.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Dash, Ashutosh, and F. F. (Russ) Knapp Jr. "An overview of radioisotope separation technologies for development of 188W/188Re radionuclide generators providing 188Re to meet future research and clinical demands." RSC Advances 5, no. 49 (2015): 39012–36. http://dx.doi.org/10.1039/c5ra03890a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Rentschier, Marion, G. Glatting, E. Schneider, M. Stabin, F. F. Knapp, S. N. Reske, and J. Kotzerke. "Dosimetrische Grundlagen für die endo vaskuläre Therapie mit Re-188 zur Prävention der Restenose nach Angioplastie." Nuklearmedizin 37, no. 02 (1998): 68–72. http://dx.doi.org/10.1055/s-0038-1629795.

Full text

Abstract:

Zusammenfassung Ziel: Für die endovaskuläre Brachytherapie stehen unterschiedliche Radionuklide zur Verfügung. Ein interessantes Konzept ist die Nutzung eines flüssigen Betastrahlers in einem Ballonkatheter. Re-188 kann aus einem Generatorsystem gewonnen werden und steht somit täglich zur Verfügung. Es sollten dosimetrische Daten erhoben werden. Methode: Es wurde die radiale Abnahme der Dosis von Re-188 bei einem typischen Dilatationskatheter (Durchmesser 3 mm, Länge 20 mm) berechnet und mit TLD-Messungen verglichen. Ergebnisse: Bei einer spezifischen Aktivität von 370 MBq/ml konnten 0,3 Gy pro 1 min in 0,5 mm Abstand von der Ballonwand gemessen werden. Doppelmessungen wiesen eine Abweichung von 3% auf. Ein schneller Dosisabfall von 50% innerhalb von 0,5 mm bzw. von 90% innerhalb von 2,5 mm wurde beobachtet. Meßwerte und Berechnungen stimmten gut überein. Die Daten von Re-188 und Y-90 entsprechen sich weitgehend. Schlußfolgerung: Berechnungen über die Dosisverteilung von Re-188 stimmen mit TLD-Messungen gut überein. Bei einer spezifischen Aktivität von 1,85 GBq/ml können in 2-3 Minuten 10-15 Gy an der Gefäßwand einer Koronararterie appliziert werden. Gegenüber radioaktiven Stents oder radioaktiven Drähten bietet sich hiermit eine einfache Alternative für die Prävention der Restenose an.

APA, Harvard, Vancouver, ISO, and other styles

12

Hübinger, Lisa, Roswitha Runge, Tobias Rosenberg, Robert Freudenberg, Jörg Kotzerke, and Claudia Brogsitter. "Psoralen as a Photosensitizers for Photodynamic Therapy by Means of In Vitro Cherenkov Light." International Journal of Molecular Sciences 23, no. 23 (December 3, 2022): 15233. http://dx.doi.org/10.3390/ijms232315233.

Full text

Abstract:

Possible enhancements of DNA damage with light of different wavelengths and ionizing radiation (Rhenium-188—a high energy beta emitter (Re-188)) on plasmid DNA and FaDu cells via psoralen were investigated. The biophysical experimental setup could also be used to investigate additional DNA damage due to photodynamic effects, resulting from Cherenkov light. Conformational changes of plasmid DNA due to DNA damage were detected and quantified by gel electrophoresis and fluorescent staining. The clonogene survival of the FaDu cells was analyzed with colony formation assays. Dimethyl sulfoxide was chosen as a chemical modulator, and Re-188 was used to evaluate the radiotoxicity and light (UVC: λ = 254 nm and UVA: λ = 366 nm) to determine the phototoxicity. Psoralen did not show chemotoxic effects on the plasmid DNA or FaDu cells. After additional treatment with light (only 366 nm—not seen with 254 nm), a concentration-dependent increase in single strand breaks (SSBs) was visible, resulting in a decrease in the survival fraction due to the photochemical activation of psoralen. Whilst UVC light was phototoxic, UVA light did not conclude in DNA strand breaks. Re-188 showed typical radiotoxic effects with SSBs, double strand breaks, and an overall reduced cell survival for both the plasmid DNA and FaDu cells. While psoralen and UVA light showed an increased toxicity on plasmid DNA and human cancer cells, Re-188, in combination with psoralen, did not provoke additional DNA damage via Cherenkov light.

APA, Harvard, Vancouver, ISO, and other styles

13

Petriev, V. M., V. K. Tishchenko, A. A. Mikhailovskaya, and A. G. Konoplyannikov. "Pharmacokinetics of Re-188-nanodiamonds complex in mice bearing experimental Ehrlich carcinoma." "Radiation and Risk" Bulletin of the National Radiation and Epidemiological Registry 26, no. 2 (2017): 62–71. http://dx.doi.org/10.21870/0131-3878-2017-26-2-62-71.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Marinelli, Mario, Licia Minguzzi, and Adriano Duatti. "An alternative approach for labeling monoclonal antibodies with Re-186 and Re-188." Applied Radiation and Isotopes 45, no. 3 (March 1994): 396–97. http://dx.doi.org/10.1016/0969-8043(94)90085-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Wang, Yangyun, Linlin Li, Xingpeng Shi, Liu Dong, Yihang Yang, Youjiu Zhang, Guolin Wu, and Ran Zhu. "Radionuclide 188 Re‐Loaded Photothermal Hydrogel for Cancer Theranostics." Particle & Particle Systems Characterization 37, no. 2 (January 20, 2020): 1900421. http://dx.doi.org/10.1002/ppsc.201900421.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Häfeli, Urs O., William K. Roberts, Gayle J. Pauer, Stine-Kathrein Kraeft, and Roger M. Macklis. "Stability of biodegradable radioactive rhenium (Re-186 and Re-188) microspheres after neutron-activation." Applied Radiation and Isotopes 54, no. 6 (June 2001): 869–79. http://dx.doi.org/10.1016/s0969-8043(00)00313-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Aboul-Enein, Mohamed Saad, William R. C. Knight, Daniel Foley, Luke McKnickle, Harrison Carter, and James A. Gossage. "Are routine post drain removal chest x-rays necessary after oesophagectomy?" International Surgery Journal 7, no. 10 (September 23, 2020): 3187. http://dx.doi.org/10.18203/2349-2902.isj20204111.

Full text

Abstract:

Background: Routine chest X-rays (CXR) are often performed following the removal of chest drains placed during oesophagectomy. CXRs are costly and inconvenient for the patient, often being performed out of working hours. The aim of this study was to evaluate whether routine CXR is necessary following drain removal or if CXRs should only be performed when indicated by the clinical status of the patient.Methods: This was a retrospective study of oesophagectomies performed at a single high volume centre. Routine post chest drain removal CXRs were analyzed and compared to baseline post-operative CXRs. The clinical status of the patient before and after chest drain removal was recorded.Results: 188 patients were identified. 111/188 (59%) had a pleural effusion or pneumothorax on their baseline post-operative CXR. Abnormal findings on post drain removal CXR were common with 72/188 (38.3%) patients having a new or worse pleural effusion or pneumothorax. Only, 5.6% (11/188) of these patients actually developed clinical signs after chest drain removal. Of these, only 2.1% (4/188) required chest drain re-insertion. No patients underwent intervention without showing clinical deterioration. No re-intervention was prompted by CXR finding alone.Conclusions: Routine CXR following chest drain removal is unnecessary. It is safe to only perform CXRs on patients who develop clinical signs.

APA, Harvard, Vancouver, ISO, and other styles

18

Iller, E., H. Polkowska-Motrenko, W. Łada, D. Wawszczak, M. Sypuła, K. Doner, M. Konior, J. Milczarek, J. Żołądek, and J. Ráliš. "Studies of gel metal-oxide composite samples as filling materials for W-188/Re-188 generator column." Journal of Radioanalytical and Nuclear Chemistry 281, no. 1 (June 27, 2009): 83–86. http://dx.doi.org/10.1007/s10967-009-0075-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Bhusari, Priya, Jaya Shukla, Munish Kumar, Rakhee Vatsa, Anupriya Chhabra, Kanchan Palarwar, Yogesh Rathore, et al. "Noninvasive treatment of keloid using customized Re-188 skin patch." Dermatologic Therapy 30, no. 5 (June 16, 2017): e12515. http://dx.doi.org/10.1111/dth.12515.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Höher, Martin, Jochen Wöhrle, Markus Wohlfrom, Hartmut Hanke, Rainer Voisard, Hans H. Osterhues, Matthias Kochs, Sven N. Reske, Vinzenz Hombach, and Jörg Kotzerke. "Intracoronary β-Irradiation With a Liquid 188 Re-Filled Balloon." Circulation 101, no. 20 (May 23, 2000): 2355–60. http://dx.doi.org/10.1161/01.cir.101.20.2355.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Shukla, Jaya, G. P. Bandopadhyaya, S. A. Shamim, and R. Kumar. "Characterization of Re-188–Sn microparticles used for synovitis treatment." International Journal of Pharmaceutics 338, no. 1-2 (June 2007): 43–47. http://dx.doi.org/10.1016/j.ijpharm.2007.01.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Zamora, Paul O., Shigemasa Osaki, Prantika Som, John A. Ferretti, Jeanie S. Choi, Chen-ze Hu, Ray Tsang, et al. "Radiolabeling brachytherapy sources with re-188 through chelating microfilms: Stents." Journal of Biomedical Materials Research 53, no. 3 (2000): 244–51. http://dx.doi.org/10.1002/(sici)1097-4636(2000)53:3<244::aid-jbm9>3.0.co;2-f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Hernández-Valdés, Daniel, Roger Alberto, and Ulises Jáuregui-Haza. "Quantum chemistry calculations of technetium and rhenium compounds with application in radiopharmacy: review." RSC Advances 6, no. 108 (2016): 107127–40. http://dx.doi.org/10.1039/c6ra23142j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Brink, Alice, Robin E. Kroon, Hendrik G. Visser, Constance E. J. van Rensburg, and Andreas Roodt. "Designing model imino bifunctional chelators for radiopharmaceuticals – in vitro antitumor activity, photoluminescence and structural analysis." New Journal of Chemistry 42, no. 7 (2018): 5193–203. http://dx.doi.org/10.1039/c7nj04208f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Paeng, Jin Chul, Dong Soo Lee, Won Jun Kang, Han-Mo Yang, June-Key Chung, Jae Min Jeong, In-Ho Chae, Myoung-Mook Lee, and Myung Chul Lee. "Dosimetry in leakage of 188 Re-DTPA during intracoronary balloon brachytherapy." European Journal of Nuclear Medicine and Molecular Imaging 30, no. 9 (September 1, 2003): 1263–65. http://dx.doi.org/10.1007/s00259-003-1235-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Makkar, Raj, James Whiting, Alex Li, Hidehiko Honda, Michael C. Fishbein, F. F. (Russ) Knapp, Jörg Hausleiter, Frank Litvack, and Neal L. Eigler. "Effects of β – -Emitting 188 Re Balloon in Stented Porcine Coronary Arteries." Circulation 102, no. 25 (December 19, 2000): 3117–23. http://dx.doi.org/10.1161/01.cir.102.25.3117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Uccelli, Licia, Micol Pasquali, Alessandra Boschi, Melchiore Giganti, and Adriano Duatti. "Automated preparation of Re-188 lipiodol for the treatment of hepatocellular carcinoma." Nuclear Medicine and Biology 38, no. 2 (February 2011): 207–13. http://dx.doi.org/10.1016/j.nucmedbio.2010.08.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Kwon Koo, Bon, Myoung-Mook Lee, Woo-Young Chung, In-Ho Chai, Hyosoo Kim, Byoung-Hee Oh, Young-Bae Park, and Yun-Shik Choi. "Effect of -irradiation with 188 Re-filled long-balloon on reference segments." Journal of the American College of Cardiology 41, no. 6 (March 2003): 9. http://dx.doi.org/10.1016/s0735-1097(03)80035-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Kotzerke, J., A. Gabelmann, and H. Hanke. "Rezidivierende Nierenarterienstenose - endovaskulÃ¤re Brachytherapie mit einem Rhenium-188-gefÃ¼llten Ballonkatheter." RÃ¶Fo - Fortschritte auf dem Gebiet der RÃ¶ntgenstrahlen und der bildgebenden Verfahren 174, no. 9 (September 2002): 1176–78. http://dx.doi.org/10.1055/s-2002-33927.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Borza, Virginia Nazarica, Elena Neacsu, Catalina Mihaela Barna, Nicoleta Popescu Pogrion, Ionel Mercioniu, and Cristina Lavinia Nistor. "Preparation of human serum albumin nanospheres labelled with ¹⁸⁸Re." International Journal of Nano and Biomaterials 2, no. 6 (2009): 547. http://dx.doi.org/10.1504/ijnbm.2009.028343.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Blower, P. J., A. G. Kettle, M. J. OʼDoherty, A. J. Coakley, and F. F. Knapp. "5. Tc-99m(V)DMSA quantitatively predicts Re-188(V)DMSA distribution." Nuclear Medicine Communications 21, no. 4 (April 2000): 370. http://dx.doi.org/10.1097/00006231-200004000-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Bolzati, C., M. Santimaria, A. Boschi, L. Uccelli, A. Duatti, P. Riva, and A. Piffanelli. "An improved procedure for the efficient labeling of antibodies with Re-188." Journal of Labelled Compounds and Radiopharmaceuticals 44, S1 (May 2001): S564—S566. http://dx.doi.org/10.1002/jlcr.25804401200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Kleynhans, Janke, Adriano Duatti, and Cristina Bolzati. "Fundamentals of Rhenium-188 Radiopharmaceutical Chemistry." Molecules 28, no. 3 (February 3, 2023): 1487. http://dx.doi.org/10.3390/molecules28031487.

Full text

Abstract:

The β− emitter, rhenium-188 (188Re), has long been recognized as an attractive candidate for targeted cancer radionuclide therapy (TRNT). This transition metal shares chemical similarities with its congener element technetium, whose nuclear isomer technetium-99m (99mTc) is the current workhorse of diagnostic nuclear medicine. The differences between these two elements have a significant impact on the radiolabelling methods and should always receive critical attention. This review aims to highlight what needs to be considered to design a successful radiopharmaceutical incorporating 118Re. Some of the most effective strategies for preparing therapeutic radiopharmaceuticals with 188Re are illustrated and rationalized using the concept of the inorganic functional group (core) and a simple ligand field theoretical model combined with a qualitative definition of frontiers orbitals. Of special interest are the Re(V) oxo and Re(V) nitrido functional groups. Suitable ligands for binding to these cores are discussed, successful clinical applications are summarized, and a prediction of viable future applications is presented. Rhenium-188 decays through the emission of a high energy beta particle (2.12 MeV max energy) and a half-life of 16.9 h. An ideal biological target would therefore be a high-capacity target site (transporters, potential gradients, tumour microenvironment) with less emphasis on saturable targets such as overexpressed receptors on smaller metastases.

APA, Harvard, Vancouver, ISO, and other styles

34

Tishchenko, V. K., V. M. Petriev, O. A. Smoryzanova, and A. A. Mikhailovskaya. "Effect of chemical structure of some phosphonic acids labeled with Re-188 on their behavior in laboratory animals." "Radiation and Risk" Bulletin of the National Radiation and Epidemiological Registry 26, no. 1 (2017): 78–88. http://dx.doi.org/10.21870/0131-3878-2017-26-1-78-88.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Krishnaraj, Maithreyi. "Shirley Pendlebury, ‘Feminism, Epistemology and Education’." Indian Journal of Gender Studies 27, no. 3 (August 23, 2020): 474–78. http://dx.doi.org/10.1177/0971521520939287.

Full text

Abstract:

The following piece contains the reflections of Maithreyi Krishnaraj, a wellknown senior feminist scholar on ‘Feminism, Epistemology and Education’ by Shirley Pendlebury, in David Car( Ed.) Education, Knowledge and Truth (Routledge, 1998, pp. 174–188). Re-visiting it after twenty years, she feels that Pendlebury’s views still have relevance.

APA, Harvard, Vancouver, ISO, and other styles

36

LIN, W. "Evaluation of three Re-188-candidates for intravascular radiation therapy to prevent restenosis." Journal of Nuclear Cardiology 6, no. 1 (February 1999): S54. http://dx.doi.org/10.1016/s1071-3581(99)90330-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Altunay, Betül, Andreas Vogg, Levente Meszaros, and Felix Mottaghy. "Radiolabeling of HER2 targeting single domain antibody with Tc-99m and Re-188." Nuclear Medicine and Biology 114-115 (November 2022): S6. http://dx.doi.org/10.1016/s0969-8051(22)02114-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Cyr, John E., Daniel A. Pearson, David M. Wilson, Carol A. Nelson, Mary Guaraldi, Michael T. Azure, John Lister-James, Ludger M. Dinkelborg, and Richard T. Dean. "Somatostatin Receptor-Binding Peptides Suitable for Tumor Radiotherapy with Re-188 or Re-186. Chemistry and Initial Biological Studies." Journal of Medicinal Chemistry 50, no. 6 (March 2007): 1354–64. http://dx.doi.org/10.1021/jm061290i.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

van Luenen, Sanne, Vivian Kraaij, Philip Spinhoven, Tom F. Wilderjans, and Nadia Garnefski. "Exploring Mediators of a Guided Web-Based Self-Help Intervention for People With HIV and Depressive Symptoms: Randomized Controlled Trial." JMIR Mental Health 6, no. 8 (August 23, 2019): e12711. http://dx.doi.org/10.2196/12711.

Full text

Abstract:

Background Cognitive behavioral therapy (CBT) is frequently used to treat depressive symptoms in people living with HIV. We developed an internet-based cognitive behavioral intervention for people with HIV and depressive symptoms, which was based on an effective self-help booklet. The Web-based intervention was previously found to be effective. Objective The objective of this study was to investigate potential mediators of the Web-based intervention. Methods This study was part of a randomized controlled trial, in which the intervention was compared with an attention-only waiting list control condition. Participants were 188 (97 in intervention group and 91 in control group) people with HIV and mild to moderate depressive symptoms recruited in HIV treatment centers in the Netherlands. A total of 22 participants (22/188, 11.7%) in the study were female and 166 (166/188, 88.3%) were male. The average age of the participants was 46.30 years (SD 10.63). The intervention comprised Web-based self-help CBT for 8 weeks, 1 to 2 hours a week, including minimal telephone support from a coach. The participants received Web-based questionnaires at pretest, 3 times during the intervention/or waiting period, and post intervention. The outcome was depressive symptoms. Factors tested as potential mediators were changes in behavioral activation, relaxation, the cognitive coping strategies catastrophizing and positive refocusing, goal re-engagement, and coping self-efficacy. Results Using multilevel structural equation modeling, changes in behavioral activation (P=.006) and goal re-engagement (P=.009) were found to be significant mediators of the intervention effect. The mediation effect seemed to occur between weeks 3 and 5 for behavioral activation and weeks 1 and 3 for goal re-engagement. Using (bivariate) autoregressive latent trajectory analysis, we found a return effect (from the dependent variable to the mediator) for goal re-engagement but not for behavioral activation, which suggested that the mediation effect of changes in behavioral activation was stronger than that in goal re-engagement. Conclusions The results suggest that changes in behavioral activation and goal re-engagement may mediate the effect of the Web-based intervention for people with HIV and depressive symptoms. The results may lead to possible mechanisms of change of the intervention and improvement of therapy outcomes. Clinical Trial Netherlands Trial Register NTR5407; https://www.trialregister.nl/trial/5298

APA, Harvard, Vancouver, ISO, and other styles

40

Xiao, Jie, Xiaobo Xu, Xiao Li, Yanli Li, Guobing Liu, Hui Tan, Hua Shen, Hongcheng Shi, and Dengfeng Cheng. "Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer." Molecules 21, no. 10 (September 30, 2016): 1308. http://dx.doi.org/10.3390/molecules21101308.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Borza, Virginia Nazarica, Elena Neacsu, Catalina Mihaela Barna, Nicoleta Popescu Pogrion, Ionel Mercioniu, and Cristina Lavinia Nistor. "Labelling of albumin microspheres with ¹⁸⁸Re: a possible agent for radiotherapy." International Journal of Nano and Biomaterials 2, no. 6 (2009): 540. http://dx.doi.org/10.1504/ijnbm.2009.028342.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Chan, Chung Ying, and Peter J. Barnard. "Rhenium complexes of bidentate, bis-bidentate and tridentate N-heterocyclic carbene ligands." Dalton Transactions 44, no. 44 (2015): 19126–40. http://dx.doi.org/10.1039/c5dt03295d.

Full text

Abstract:

Rhenium(i) tricarbonyl complexes of a range of bidentate, bis-bidentate and tridentate NHC ligands have been prepared. These NHC ligands are of interest for possible applications in the development of Tc-99m or Re-186/188 radiopharmaceuticals and the stability of two complexes were evaluated in ligand challenge experiments using the metal binding amino acids l-histidine or l-cysteine.

APA, Harvard, Vancouver, ISO, and other styles

43

Truitt, K. E., T. Nagel, L. F. Suen, and J. B. Imboden. "Structural requirements for CD28-mediated costimulation of IL-2 production in Jurkat T cells." Journal of Immunology 156, no. 12 (June 15, 1996): 4539–41. http://dx.doi.org/10.4049/jimmunol.156.12.4539.

Full text

Abstract:

Abstract Although under certain conditions an association with phosphatidylinositol 3'-kinase (PI3-K) appears to be critical for CD28 signaling, mutation of the PI3-K binding site (Tyr 170) does not alter the costimulatory ability of murine CD28 (mCD28) in Jurkat T cells. To define the structural requirements for this PI3-K-independent signaling, we expressed a series of mCD28 mutants in Jurkat. Mutation to Phe of all four cytoplasmic Tyr residues together (ALL F mutant) greatly reduced the ability of mCD28 to augment IL-2 production. Isolated re-constitution of Tyr 188, but not 170, 185, or 197, restored the ability of ALL F mCD28 to deliver a costimulus. Thus, a signal based upon Tyr 188 can deliver a costimulus for the enhancement of IL-2 production by Jurkat cells.

APA, Harvard, Vancouver, ISO, and other styles

44

ZAMORA, P. O., H. BENDER, F. F. (RUSS) KNAPP, B. A. RHODES, and H. J. BIERSACK. "Targeting Peptides for Pleural Cavity Tumor Radiotherapy: Specificity and Dosimetry of Re-188-RC-160." Hybridoma 16, no. 1 (February 1997): 85–91. http://dx.doi.org/10.1089/hyb.1997.16.85.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Banka, Vinay Kumar, Sung-Hyun Moon, Sudhakara Reddy Seelam, Yun-Sang Lee, and Jae Min Jeong. "Development of HDD kit for preparation of liver cancer therapeutic agent Re-188-HDD/lipiodol." Nuclear Medicine and Biology 41, no. 7 (August 2014): 639. http://dx.doi.org/10.1016/j.nucmedbio.2014.05.024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

GARCIAGARAYOA, E., R. SCHIBLI, and P. SCHUBIGER. "Peptides radiolabeled with Re-186/188 and Tc-99m as potential diagnostic and therapeutic agents." Nuclear Science and Techniques 18, no. 2 (April 2007): 88–100. http://dx.doi.org/10.1016/s1001-8042(07)60026-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Adams, Christopher Peter, and Wasif M. Saif. "Targeted radiopeptide therapy Re188-P2045 to treat neuroendocrine lung cancer." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e20016-e20016. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e20016.

Full text

Abstract:

e20016 Background: : Despite the recent success of checkpoint inhibitors, there continues to be a significant medical need for lung cancer therapies that can be directed to the patients most likely to respond. Somatostatin receptor subtype 2 (SSTR2) is the most widely up-regulated subtype in both small and non-small cell lung cancers and is also expressed in tumoral (but not mature) blood vessels. Peptide targeted radiotherapy has advantages over traditional targeted therapies in that targeted tumor cells as well as surrounding cancer cells and supporting stroma are selectively killed. This study was conducted to determine the ability of Rhenium Re 188 P2045, a radiolabeled somatostatin analog specific for SSTR2 to both image (to select the most appropriate patients) and treat lung cancer patients who over-express somatostatin receptors. Methods: In an open label, single arm study, refractory lung cancer patients to standard of care therapy were identified by image analysis using Rhenium Re 188 P2045, a radiolabeled somatostatin analog. 25 Patients received the imaging dose of 10uCi of Re188 and 265ng of peptide by intravenous injection. Three patients were selected based on high SSTR expression levels to receive 30uCi of Re188 P2045 as a therapeutic dose 14 days after imaging. Patients were followed for 8 weeks post treatment. Results: The imaging study revealed a high density of expression of the somatostatin receptor in the lungs of patients. Patients in the imaging and therapeutic treatment groups reported no adverse advents or signs of toxicity. The image analysis using Re188 P2045 was compared to CT images and demonstrated accurate detection of lung tumor lesions. The images obtained using Re188 P2045 were of sufficiently high quality to enable identification of receptor expression at the tumor site as shown in Figures 1&2. Conclusions: Rhenium Re 188 P2045, a radiolabeled somatostatin analog, may be used to both identify and treat lung cancer tumors. The ability to image and dose patients with the same targeted molecule enables a personalized medicine approach and this highly targeted patient therapy may significantly improve treatment of tumors that over express somatostatin receptor.

APA, Harvard, Vancouver, ISO, and other styles

48

SHEN, SHUI-FA, XIU-JIE WANG, TING-TAI WANG, TING-DUN WEN, JIAN-ZHONG GU, ZHONG-DONG LIU, ZE-SHENG ZHANG, FU-RONG XU, SHI-JIE ZHENG, and JING-YI LIU. "DECAY OF 188Re AND TRS CALCULATIONS FOR ITS DAUGHTER NUCLIDE 188Os." International Journal of Modern Physics E 18, no. 07 (August 2009): 1603–14. http://dx.doi.org/10.1142/s0218301309013762.

Full text

Abstract:

The γ-ray spectra of 188 Re decay have been studied by using a Compton-suppressed spectrometer and a three parameters γ-γ- T list coincidence system. Experimental data analysis demonstrated that six γ-rays at 557, 810, 1463, 1867, 1936 and 2022 keV and three levels at 1443, 1936 and 2022 keV are confirmed again. Seven new γ-rays at 309.60±0.04, 826.90±0.02, 979.29±0.08, 1103.7±0.4, 1828.2±0.1, 1842.5±0.2 and 1982.5±0.2 keV have been identified, three new levels at 309.60, 1828.2 and 1982.5 keV are assigned. The β- decay branching ratio is deduced. In addition, in order to study this γ-unstable nucleus, shape calculations using the Hartree–Fock–Bogoliubov-like formalism were carried out for positive-parity states in 188 Os . The TRS plots reveal that, as the spin increases up the band, the triaxiality parameter γ changes.

APA, Harvard, Vancouver, ISO, and other styles

49

Laumets, Rauno, Karel Viigipuu, Kerli Mooses, Jarek Mäestu, Priit Purge, Ando Pehme, Priit Kaasik, and Martin Mooses. "Lower Leg Length is Associated with Running Economy in High Level Caucasian Distance Runners." Journal of Human Kinetics 56, no. 1 (February 25, 2017): 229–39. http://dx.doi.org/10.1515/hukin-2017-0040.

Full text

Abstract:

AbstractThe aim of the present study was to investigate lower limb anthropometric and composition variables related to running economy (RE) and running performance in a homogeneous group of high level European distance runners. RE at the speeds of 14, 16 and 18 km·h−1 (189 ± 12; 188 ± 11; 187 ± 11 O2 ml·kg−1·km−1) and maximal oxygen uptake (VO2max) (67.3 ± 2.9 ml·kg−1·min−1) of 13 high level distance runners were determined on a motorised treadmill. Anthropometric variables and body composition were measured. The BMI was related to RE at the speed of 14 (r2 = 0.434; p = 0.014), 16 (r2 = 0.436; p = 0.014) and 18 km·h−1 (r2 = 0.389; p = 0.023). Lower leg length was negatively related to RE at the speed of 16 and showed such a tendency at the speed of 14 and 18 km·h−1. VO2max indicated a moderate relationship with RE at the speeds of 14, 16 and 18 km·h−1 (r2 = 0.372, p = 0.030; r2 = 0.350, p = 0.033; r2 = 0.376, p = 0.026, respectively) which was confirmed by subsequent partial correlation analysis. While lower leg length and the BMI presented a relationship with RE, none of the calculated body composition and anthropometric proportions were related to RE or performance. The relationship between RE and VO2max would confirm the notion that RE could be at least partly compensated by VO2max to achieve high performance results.

APA, Harvard, Vancouver, ISO, and other styles

50

Haase, Michael G., Knut Liepe, Diana Faulhaber, Gerd Wunderlich, Michael Andreeff, Roland Jung, Gustavo B. Baretton, Guido Fitze, and Jörg Kotzerke. "Dose-dependent histological alterations in the rat lung following intravenous application of Re-188-labeled microspheres." International Journal of Radiation Biology 89, no. 10 (May 14, 2013): 863–69. http://dx.doi.org/10.3109/09553002.2013.794320.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!